Government Owned Invention Available for License: T Cell Receptors Targeting HPV 6 or HPV 11

Issuing agencies

Abstract

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 162 (Monday, August 24, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 162 (Monday, August 24, 2026)]
[Notices]
[Pages 54728-54729]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-17188]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government Owned Invention Available for License: T Cell 
Receptors Targeting HPV 6 or HPV 11

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute (NCI) seeks research co-
development partners and/or licensees for a collection of T cell 
receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this license 
opportunity should be directed to Suna Gulay French Ph.D., Technology 
Transfer Manager, NCI, Technology Transfer Center, Email: 
<a href="/cdn-cgi/l/email-protection#cebdbba0afe0a9bba2afb78ea0a7a6e0a9a1b8"><span class="__cf_email__" data-cfemail="a3d0d6cdc28dc4d6cfc2dae3cdcacb8dc4ccd5">[email&#160;protected]</span></a> or Phone: 240-276-7424.

SUPPLEMENTARY INFORMATION: Recurrent Respiratory Papillomatosis (RRP) 
and anogenital condyloma arise from chronic infection with human 
papillomavirus (HPV) 6 or 11. They can cause significant morbidity due 
to persistent papillomatous growths in the upper aerodigestive or 
anogenital tract. In RRP, lesions may obstruct the airway (leading to 
dysphonia), dyspnea, recurrent pneumonia, or pulmonary failure. In rare 
cases, it may progress to malignancy. Current treatment options for RRP 
include zopapogene imadenovec (Papzimeos), systemic bevacizumab, and 
repeated surgical debulking. Papzimeos can lead to durable responses in 
some patients but remains ineffective against pulmonary disease. 
Systemic bevacizumab can control disease, but prolonged use can lead to 
intolerable toxicities. Repeat surgical debulking causes cumulative 
surgical and anesthetic risks. Therefore, there remains a critical 
unmet need for

[[Page 54729]]

safe and effective therapies for patients with aggressive or pulmonary 
RRP refractive to standard-of-care treatments.
    Researchers at the NCI identified several T cell receptors (TCRs) 
with potential utility in adoptive cell therapy and other TCR-based 
approaches to treat HPV 6- or HPV 11-associated diseases--including 
RRP. These TCRs used engineered T cells derived from peripheral blood 
mononuclear cells (PBMCs), an easily accessible source of human immune 
cells. The engineered T cells demonstrated reproducible, antigen-
specific recognition of multiple HPV 6 and HPV 11 proteins presented by 
diverse HLA class I subtypes. The inventors further showed that these 
TCR-engineered T cells effectively eliminated HPV 6/11-infected target 
cells. Such results support the therapeutic potential of these TCRs for 
HPV-associated disease. The intellectual property rights have been 
assigned to the Government of the United States of America.
    ``This Notice is in accordance with 37 CFR 404.4 Authority to grant 
licenses.''
    NIH Reference Number: E-002-2026-0.
    Related Technologies: E-143-2024-0 and E-019-2025-0.
    Product Type: Therapeutic.
    Therapeutic Area(s): Immunology [verbar] Infectious Disease 
[verbar] Oncology.
    Development Stage: Pre-clinical (in vivo validation).
    Publications: N/A.
    Patent(s): Provisional patent application.
    Potential Commercial Applications:
    <bullet> Treatment and diagnosis of recurrent RRP and other 
premalignant and nonmalignant conditions.
    [cir] Adoptive cell therapy.
    [cir] TCR-based therapy.
    [cir] Combination therapy.
    <bullet> Treatment and diagnosis of additional HPV 6- or HPV 11-
associated diseases and chronic infections.
    [cir] Adoptive cell therapy.
    [cir] TCR-based therapy.
    [cir] Combination therapy.
    Competitive Advantages:
    <bullet> Novel adoptive cell therapies, either as monotherapies or 
in combination with other therapeutic modalities.
    <bullet> Promising freedom to practice as part of a comprehensive 
intellectual property portfolio for RRP therapeutics and diagnostics.
    <bullet> Established FDA regulatory precedent for TCR-based 
therapeutics.
    <bullet> Opportunity to qualify for regulatory incentives for rare 
diseases, including: orphan drug designation, priority review, and 
breakthrough therapy designation.
    Collaboration Opportunity: Researchers at the NCI seek licensing 
and/or co-development research collaborations for a collection of T-
cell receptors (TCRs) that specifically target HPV 6 or HPV 11 
antigens.

     Dated: August 19, 2026.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2026-17188 Filed 8-21-26; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>